<noscript id="2mmmm"><acronym id="2mmmm"></acronym></noscript>
  • <tt id="2mmmm"></tt>
  • <tt id="2mmmm"><rt id="2mmmm"></rt></tt>
  • <table id="2mmmm"></table>
  • <tt id="2mmmm"><rt id="2mmmm"></rt></tt>
    <tt id="2mmmm"><table id="2mmmm"></table></tt>
    中文
    中文
    為了病患而驅動(dòng)的創(chuàng )新
    Patient-first cell therapy innovation

    2022
    • 0
    Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy. 
    Cancer Cell 40, 674-693, June 13, 2022    doi:https://doi.org/10.1016/j.ccell.2022.04.018

    Haixia Long, Qingzhu Jia, Liuyang Wang, Wenfeng Fang, Zhongyu Wang, Tao Jiang, Fei Zhou, Zheng Jin, Jiani Huang, Li Zhou, Chunyan Hu, Xinxin Wang, Jin Zhang, Yujie Ba, Yujie Gong, Xianghua Zeng, Dong Zeng, Xingxing Su, Peter B. Alexander, Li Wang, Limei Wang, Yisong Y. Wan, Xiao-Fan Wang, Li Zhang, Qi-Jing Li, Bo Zhu ( 2022)   

    Breaking boundaries: current progress of anticancer NK cell-based drug development
    Drug Discovery Today, PII: S1359-6446(22)00429-9 doi: https://doi.org/10.1016/j.drudis.2022.103436
    Reference: DRUDIS 103436
    Shuhang Wang, Kun Chen, Yale Jiang, Guo Zhao, Caie Wang, Hong Fang, Qiyu Tang, Chao Sun, Liang Zhang, Haiyang Wu, Li-Feng Zhang, Ning Li 

     
    • 上一篇:--
    • 下一篇:2021
    06.14
    2022
    來(lái)源:
    關(guān)鍵詞:
    相關(guān)閱讀

    Copyright ? 2019 天科雅生物醫藥科技有限公司

    粵公網(wǎng)安備 44011502000528號

    粵ICP備20056630號 Powered by vancheer
    關(guān)于天科雅
    研究與發(fā)展
    產(chǎn)品及臨床
    新聞與媒體
    招賢納士

    Copyright ? 2019 天科雅生物醫藥科技有限公司

    粵公網(wǎng)安備 44011502000528號

    粵ICP備20056630號 Powered by vancheer
    精品无码国产自产在线观看水浒传_西西人体444WwW高清大胆_国产探花在线精品一区二区_成人试看120秒体验区